Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT ID: NCT01756053

Last Updated: 2014-10-29

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2014-01-31

Brief Summary

This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit attempt (~4 days). The key cognitive domains include: working memory, sustained attention, and response inhibition.

Detailed Description

This is a single-site, phase IIa, double-blind, within-subject, cross-over, human laboratory study. Subjects will be healthy, treatment-seeking female and male adult smokers, ages 18 to 65 years old. Subjects deemed eligible for participation after an Intake Visit (~Day -7) will complete baseline assessments and receive period 1 medication (ABT-089 or placebo) at the Baseline Visit (Day 0). Subjects will take 40mg of ABT-089 or placebo, based on random assignment, every day for two identical 10-day study treatment periods.

Subjects will begin period 1 study medication on Day 1. On Days 3 and 5, subjects will complete in-clinic medication run-up and monitoring assessments. On Day 5, subjects will begin a ~24-hour period of mandatory abstinence from smoking. Day 6 is conducted in two parts. Part 1 will consist of confirmation of smoking abstinence, testing for abstinence-induced cognitive deficits and the collection of subjective assessments. Part 2 will begin with a programmed smoking lapse, after which the subjective rewarding value of the programmed lapse cigarette will be assessed. Before leaving the clinic on Day 6, subjects will receive brief cessation counseling and be instructed to try to remain abstinent from 10pm that evening until after the final Observation Visit on Day 10.

During the ~4-day monitored abstinence/observation phase, subjects will complete in-clinic observation visits (subjective assessments, medication adherence, etc.) on Days 7, 8, and 10.

After a ~3-week medication washout period and Period 2 Medication Pick-up Visit on ~Day 31, subjects will begin study medication (either ABT-089 or placebo; but will always be the opposite of the assigned study medication in period 1) and participate in period 2 of the study following the same procedures as period 1.

Conditions

Nicotine Addiction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

ABT-089

During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.

Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules.

Group Type: ACTIVE_COMPARATOR

ABT-089

Intervention Type: DRUG

Selective neuronal nicotinic receptor agonist.

Placebo

These are matched placebo capsules manufactured by the study drug supplier.

During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.

Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matched placebo capsules supplied by study drug supplier.

Interventions

ABT-089

Selective neuronal nicotinic receptor agonist.

Intervention Type: DRUG

Placebo

Matched placebo capsules supplied by study drug supplier.

Intervention Type: DRUG

Other Intervention Names

Pozanicline

Eligibility Criteria

Inclusion Criteria

Eligible subjects will be:

1. Male and female smokers who are between 18 and 65 years of age and self-report smoking at least 10 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months.

2. Healthy as determined by the Study Physician, based on relevant medical history, physical examination (including vitals), and basic screening tests (CBC, CHEM7, AST/ALT).

3. Smokers who wish to quit smoking in the next 2-6 months (treatment-seeking), because our prior work suggests that motivated subjects are more sensitive to medication effects on smoking behavior. Using a scale from 0 to 100 (100, being extremely interested), subjects must rate their interest in quitting smoking within the next 6 months greater than 50.

4. Able to communicate fluently in English (speaking, writing, and reading).

5. Plan to live in the area for the next 2 months.

6. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.

Exclusion Criteria

Subjects who self-report and/or present with the following criteria will not be eligible to participate in the study:

1. Smoking behavior.

1. Current enrollment or firm plans to quit smoking and/or enroll in a smoking cessation program within the next 2 months.

2. Current and/or anticipated use of any nicotine substitutes and/or smoking cessation treatments/medications within the next 2 months.

3. Provide a Carbon Monoxide (CO) reading less than 11 parts per million (ppm) at Intake.

4. Provide a CO reading of 10 ppm or greater at either Testing Visit (Days 6 and 37). If the CO reading is greater than or equal to 10 ppm, but there is a 50% reduction from the CO reading collected at the Baseline/Period 1 Medication Pick-Up Visit, this will be sufficient and the subject may continue as scheduled.

5. Self-report smoking during the mandatory abstinence period at either Testing Visit (Days 6 and 37).

6. Regular use of chewing tobacco or snus.

2. Alcohol/Drugs.

1. History of substance abuse in the past 6 months and/or currently receiving treatment for substance abuse (e.g., alcohol, opioids, cocaine, marijuana, or stimulants). Subjects reporting a history of substance abuse must be in remission at least 6 months or greater.

2. Current alcohol consumption that exceeds 25 standard drinks/week.

3. Provide a breath alcohol concentration (BrAC) reading of greater than or equal to 0.01 at Intake, Baseline/Period 1 Medication Pick-Up, or Testing Visits (Days 6 and 37).

4. A positive urine drug screen for cocaine, PCP, amphetamines, methamphetamines, tricyclic antidepressants, opiates, methadone, benzodiazepines, and/or barbiturates at Intake, Baseline/Period 1 Medication Pick-Up, Period 2 Medication Pick-Up, and Observation Visits on Days 10 and 41.

3. Medical.

1. Women who are pregnant, planning a pregnancy, and/or breast feeding. All female subjects will undergo a urine pregnancy test at Intake, after which only females determined to be of childbearing potential will complete a urine pregnancy test at Baseline/Period 1 Medication Pick-Up, Period 2 Medication Pick-Up, and Observation Visits on Days 10 and 41. By signing the combined consent and HIPAA form, women of childbearing potential agree to use an approved method of contraception during the study.

2. Men who do not agree to use an approved method of contraception during the study. Men who are sexually active must be surgically sterile (vasectomy) or using a barrier method (condom) of birth control for the duration of the study. By signing the combined consent and HIPAA form, men agree to use an approved method of contraception.

3. Current treatment of cancer or diagnosed with cancer (except basal cell carcinoma) in the past 6 months.

4. Any impairment including, but not limited to, visual, physical, and/or neurological impairments preventing neurocognitive task performance.

5. Color blindness.

6. History of brain injury.

7. History of epilepsy or a seizure disorder.

8. Low or borderline intellectual functioning - determined by receiving a score of less than 90 on the Shipley Institute of Living Scale (SILS, administered at Intake), which correlates with the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Estimated IQ Test.

9. Serious or unstable disease within the past 6 months (i.e., heart disease, liver/kidney failure).

10. Recent history (last 6 months) of abnormal heart rhythms, tachycardia, and/or cardiovascular disease (stroke, angina, heart attack) may result in ineligibility. These conditions will be evaluated on a case-by-case basis by the Study Physician.

11. Clinically significant abnormalities determined by physical examination and collection of vital signs at Intake. Abnormalities will be assessed by the Study Physician and eligibility will be determined on a case-by-case basis.

12. Uncontrolled hypertension (Systolic Blood Pressure [SBP] greater than or equal to 160 mmHg and/or Diastolic Blood Pressure [DBP] greater than or equal to 100 mmHg).

13. Heart rate/pulse greater than or equal to 110 beats per minute (bpm).

14. Clinically significant abnormalities in clinical chemistry (CBC, CHEM7, and AST/ALT). Results greater than 20% outside of normal range will be evaluated for clinical significance by the Study Physician and eligibility will be determined on a case-by-case basis.

15. Inability to provide an assessable blood sample for basic screening tests (CBC, CHEM7, and AST/ALT) at Intake.

4. Psychiatric.

As determined by self-report, the Mini International Neuropsychiatric Interview (MINI), and/or Columbia-Suicide Severity Rating Scale (C-SSRS):

1. Any suicide risk score on the MINI.

2. Current (past month) suicidal ideation or lifetime suicidal behavior on the C-SSRS.

3. Lifetime history or current diagnosis of psychosis, bipolar disorder, and/or schizophrenia.

5. Current or past hypomanic/manic episode.

6. History or current diagnosis of posttraumatic stress disorder (PTSD).

7. Prior or current diagnosis of attention deficit hyperactivity disorder (ADHD).

5. Medication.

1. Current use or recent discontinuation (within the last 14 days at the time of Intake) of:

• Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix).
• Anti-anxiety or panic disorder medications.
• Anti-psychotic medications.
• Medications used to treat depression (e.g., Wellbutrin, MAOIs, SSRIS, tricyclic antidepressants).
• Prescription stimulants (e.g., Provigil, Ritalin, Adderall).
• Systemic corticosteroids.

2. Current use of:

• Nicotine replacement therapy (NRT).

3. Daily use of:

• Opiate-containing medications for chronic pain.
• Inhaled corticosteroids.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Caryn Lerman, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Related Links

http://www.med.upenn.edu/cirna/

CIRNA Center homepage

Other Identifiers

815238

Identifier Type: -

Identifier Source: org_study_id